A peer-reviewed version of this preprint was published in PeerJ on 18 November 2014.

View the peer-reviewed version (peerj.com/articles/653), which is the preferred citable publication unless you specifically need to cite this preprint.

https://doi.org/10.7717/peerj.653
Placental vascular pathology and increased thrombin generation as mechanisms of disease in obstetrical syndromes

Obstetrical complications including preeclampsia, fetal growth restriction, preterm labor, preterm prelabor rupture of membranes and fetal demise are all the clinical endpoint of several underlying mechanisms (i.e. infection inflammation, thrombosis, endocrine disorder, immunologic rejection, genetic, and environmental), therefore, they may be regarded as syndromes. Placental vascular pathology and increased thrombin generation were reported in all of these obstetrical syndromes. Moreover, elevated concentrations of thrombin-anti-thrombin III complexes and changes in the coagulation as well as anticoagulation factors can be detected in the maternal circulation prior to the clinical development of the disease in some of these syndromes. In this review, we will assess the changes in the hemostatic system during normal and complicated pregnancy in maternal blood, maternal-fetal interface and amniotic fluid, and describe the contribution of thrombosis and vascular pathology to the development of the great obstetrical syndromes.
1 Placental Vascular Pathology and Increased Thrombin Generation as Mechanisms of Disease In Obstetrical Syndromes

Salvatore Andrea Mastrolia¹, Moshe Mazor², Giuseppe Loverro¹, Vered Klaitman², and Offer Erez²

¹ Department of Obstetrics and Gynecology, Azienda Ospedaliero-Universitaria Policlinico di Bari, School of Medicine, University of Bari “Aldo Moro”, Bari, Italy
² Obstetrics and Gynecology, Soroka University Medical Center, School of Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel

Corresponding author
Offer Erez M.D.
Acting director Maternal Fetal Medicine Unit
Department of Obstetrics and Gynecology
Soroka University Medical Center
School of Medicine, Faculty of Health Sciences
Ben Gurion University of the Negev
P.O.Box 151,
Beer Sheva 84101
Israel
erezof@bgu.ac.il

2. What are the great obstetrical syndromes?

2A. Introduction

Obstetrical complications including preeclampsia, fetal growth restriction, preterm labor, preterm prelabor rupture of membranes and fetal demise are all the clinical endpoint of several underlying mechanisms (i.e. infection inflammation, thrombosis, endocrine disorder, immunologic rejection, genetic, and environmental), therefore, they may be regarded as syndromes. In this review, we will assess the changes in the hemostatic system during normal and complicated pregnancy in maternal blood, maternal-fetal interface and amniotic fluid, and describe the contribution of thrombosis and vascular pathology to the development of the great obstetrical syndromes.
The major obstetrical complications including preeclampsia, intrauterine growth restriction (IUGR), preterm labor (PTL), preterm prelabor rupture of membranes (PROM), fetal demise, and recurrent abortions are all syndromes, also defined as "great obstetrical syndromes". As reported in The Oxford Medical Dictionary a syndrome is ‘a combination of symptoms and/or signs that form a distinct clinical picture indicative of a particular disorder’. Hence, they represent the clinical manifestation of many possible underlying mechanisms of disease.

Key features of these syndromes are: multiple etiologies; long preclinical stage; frequent fetal involvement; clinical manifestations which are often adaptive in nature; and predisposition to a particular syndrome is influenced by gene–environment interaction and/or complex gene-gene interactions involving maternal and/or fetal genotypes. These mechanisms of disease were identified and reported in all the obstetrical complications listed above. This review is focused on the role of thrombosis and vascular pathology of the placenta in these syndromes.

3. What are the changes in the coagulation system during normal pregnancy?

In term of the coagulation and hemostatic systems there are several major compartments: the maternal circulation, the fetal maternal interface (the placenta, and membranes), amniotic fluid and the fetus that each has a specific behavior during gestation. The changes in the coagulation system during gestation are considered to be adaptive mechanisms and are aimed to: 1) the prevention of bleeding at the time of trophoblast implantation and the delivery of the fetus; 2) allow the laminar flow and the intervillous space; and 3) seal amniotic fluid leak and reduce obstetrical bleeding. Of interest, the fetus is somewhat less involved and its coagulation system develops during gestation, and this subject is beyond the scope of this review.

Indeed, normal pregnancy has been associated with excessive maternal thrombin generation and a tendency for platelets to aggregate in response to agonists. Pregnancy is accompanied by 2 to 3-fold increase in fibrinogen concentrations and 20% to 100% increase in factors VII, VIII, IX, X, and XII, all of which peak at term. The concentrations of vWF increase up to 400% by term. By contrast, those of pro-thrombin and factor V remain unchanged while the concentrations of factors XIII and XI decline modestly. Indeed there is evidence of chronic low-level thrombin and fibrin generation throughout normal pregnancy as indicated by enhanced concentrations of pro-thrombin fragment 1.2, thrombin-antithrombin (TAT) III complexes, and soluble fibrin polymers. Free protein S concentration declines significantly (up to 55%) during pregnancy due to increased circulating complement 4B-binding protein its molecular carrier. Protein S nadir at delivery and this reduction is exacerbated by cesarean delivery and infection. As a consequence, pregnancy is associated with an increase in resistance to activated protein...
The concentrations of PAI-1 increase by 3 to 4-folds during pregnancy while plasma PAI-2 values, which are negligible before pregnancy reach concentrations of 160 mg/L at delivery. Thus, pregnancy is associated with increased clotting potential, as well as decreased anticoagulant properties, and fibrinolysis. Therefore, it can be defined as a prothrombotic state. One of the most important mediators of the hypercoagulable state of normal pregnancy is tissue factor. Indeed, there is a substantial increase in tissue factor (TF) concentrations in the decidua and myometrium, as well as preventing placental abruption. The placenta is a source of TF, since trophoblast cells constitutively express it, behaving as activated endothelium, and leading to a condition of procoagulant state that, if not controlled by anticoagulant mechanisms, predisposes to thrombotic complications. The principal anticoagulant mechanism inhibiting TF activation pathway is tissue factor pathway inhibitor (TFPI), which mRNA is highly expressed in the macrophages in the villi in term placenta.

Similarly, high TF concentrations have been detected in the fetal membranes (mainly the amnion) and amniotic fluid. TFPI has been found in amniotic fluid as well, but it is not clear if the presence of TF and its natural inhibitor is related to coagulation per se or is somehow connected with embryonic development.

In contrast to the changes detected in the amniotic fluid and the decidua, the median maternal plasma immunoreactive TF concentration of normal pregnant women do not differ significantly from that of non-pregnant patients. However, labor at term increases significantly the maternal plasma immunoreactive TF concentration in comparison to the non-pregnant state. In addition to the changes in TF, normal pregnancy is associated with increased thrombin generation, as determined by the elevation of maternal concentrations of fibrinopeptide A, prothrombin fragments (PF) 1 and 2, and thrombin–antithrombin (TAT) III complexes. The concentration of these complexes further increases during and after normal parturition, and subsequently decreases during the puerperium.

4. What are the changes in the hemostatic system associated with the great obstetrical syndrome?

The great obstetrical syndromes are associated with changes in the hemostatic and vascular systems in the compartments mentioned above: 1) the maternal circulation; 2) the feto-maternal interface of placenta and membranes; 3) and the amniotic fluid.

4.1 Changes in the hemostatic system of women with obstetrical syndromes.

The involvement of the hemostatic system in the pathophysiology of these obstetrical syndromes is becoming more and more apparent. Indeed, increased thrombin generation is reported in the
maternal circulation of women with preeclampsia, IUGR, fetal demise, PTL, and preterm PROM.

There are several possible explanations for the increased thrombin generation in these patients: 1) increased activation of the coagulation cascade in the maternal circulation due to pathological processes including bleeding or inflammation; and 2) depletion of anticoagulation proteins that subsequently leads to increased thrombin generation (Table 1).

### 4.1.1 Increased activation of the coagulation cascade and thrombin generation in the maternal circulation in patients with pregnancy complications

All the obstetrical syndromes including preeclampsia, FGR, fetal demise, PTL, and preterm PROM are associated with a higher maternal thrombin generation than a normal pregnancy. These may be of clinical implication since in women with preterm labor, elevated maternal plasma TAT III complexes concentration was associated with a higher chance to deliver within <7 days from admission (Fig. 1). To further understand how does thrombin affect the duration of pregnancy and the clinical phenotype of patients with the obstetrical syndromes we need to consider what are the mechanisms leading to thrombin generation and how it affects the feto-maternal unit.

Increased thrombin generation can result from the following underlying mechanisms: 1) decidual hemorrhage that leads to a retro-placental clot formation; 2) intra-amniotic infection/inflammation which can induce decidual bleeding and sub-clinical abruption, as well as increased intra-amniotic TAT complexes; and 3) an increased maternal systemic inflammatory response that may activate the extrinsic pathway of coagulation due to the expression and release of TF by activated monocytes.

Thrombin affects many systems including also the following: 1) stimulation of decidual cell secretion of matrix metalloproteinase (MMP) (i.e. MMP-1 and MMP-3) that can degrade the extracellular matrix of the chorioamniotic membranes (as in preterm PROM); 2) myometrial activation and uterine contractions generation that may lead to preterm labor with or without rupture of membranes and a subsequent preterm delivery; and 3) thrombin has an inhibitory effect on the production of TFPI by endothelial cells, and the increased thrombin generation observed in patients with PTL may be associated with a concomitant reduction in TFPI production by the maternal vascular endothelium (the depletion of anticoagulant proteins will be discussed in the following section of this review).

There is evidence to support that the extrinsic pathway of coagulation is activated in many of these pregnancy complications and it is the source of the increased thrombin generation. Indeed, increased immunoreactive TF concentrations were reported in women with preeclampsia and
those with preterm PROM. Moreover, the contribution of preeclampsia to elevated maternal immunoreactive TF persisted also among patients with fetal demise, while those with fetal death who were normotensive did not have higher median TF concentration than normal pregnant women. Moreover, the median TF concentration of patients with preeclampsia was also higher than in patients with fetal demise without hypertension. These findings are consistent with previous studies, suggesting that elevated TF immunoreactivity and activity may be associated with the pathophysiologic process leading to preeclampsia, rather than being a consequence of the fetal death.

In some of the obstetrical syndromes there was elevated tissue factor activity in the maternal circulation without a concomitant increase in the plasma concentration of this factor. This was the case among patients with an SGA neonate and those with preterm labor (Table 1). This suggests that the increased TF activity among patients with PTL as well as those with an SGA neonate, contributes to a higher generation of factor Xa that, along with the physiologic increase in the maternal plasma concentrations of factor VII and factor X during gestation, may be the underlying mechanism leading to the increased thrombin generation reported these syndromes.

The differences between PTL and preterm PROM in term of maternal plasma TF concentration and activity may derive from the specific component of the common pathway of parturition, which is activated in each obstetrical syndrome. While preterm PROM is associated with the activation of the decidua and the membranes, myometrial activation is the major component of preterm labor with intact membranes. This is relevant because the decidua and the membranes have a high TF concentration.

In summary, the evidence brought herein suggests that increased thrombin generation in patients with the great obstetrical syndromes may reflect the activation of the coagulation cascade mainly through the extrinsic arm. This activation can be attributed to various underlying mechanisms.

4.1.2 Depleted or insufficient anticoagulant proteins concentration

In the normal state there is a delicate balance between the proteins activating/participating the coagulation cascade and their inhibitors. Increased thrombin generation may result, as we presented above, from activation of the coagulation cascade due to higher concentrations or activities of the proteins included in the coagulation cascade. However, thrombin generation can also result from insufficient concentration or activity of anticoagulation proteins.

Tissue factor pathway inhibitor (TFPI), a glycoprotein comprising of three Kunitz domain that are specific inhibitors of trypsin-like proteinases, is the main inhibitor of the extrinsic pathway of coagulation. TFPI inhibits thrombin generation through the inactivation of activated factor X.
and the factor VIIa/TF complex. The mean maternal plasma concentrations of total TFPI increases during the first half of pregnancy, remains relatively constant in the second half and decreases during labor. There are two types of TFPI: 1) TFPI-1 is the more prevalent form in the non-pregnant state in the maternal circulation and can also be found in the fetal blood, platelets, endothelial cells and other organs; and 2) TFPI-2 - the major form of TFPI in the placenta, also known as Placental Protein 5 (PP5). During pregnancy, the maternal plasma concentration of TFPI-2 increases gradually, reaches a plateau at 36 weeks and subsides after delivery.

The overall balance between the concentration and activity of the coagulation factors and the anti-coagulation proteins is one of the determining factors of thrombin generation. In the normal state, the immunoreactive concentrations of TFPI in the plasma are 500 to 1000 times higher than that of TF, suggesting that an excess of anti-coagulant proteins closely controls the coagulation cascade activity. The median maternal plasma TFPI concentration increases during preeclampsia, which is associated with an exaggerated maternal systemic inflammatory response. However, the increase in the median maternal TF plasma concentration is such that the overall balance between TF and its inhibitor is affected leading to increased thrombin generation in this syndrome. In contrast to preeclampsia, maternal plasma TFPI concentration decreases in patients with PTL and preterm PROM regardless to the presence of intra-amniotic infection/inflammation, as well as in women with fetal demise, and does not change in mothers with SGA fetuses. Overall these findings suggest that the increased thrombin generation observed among these patients may derive not only from an increased activation of the hemostatic system, but also from insufficient anti-coagulation, as reflected by the lower TFPI concentrations (Fig. 2).

A possible explanation of the lower maternal plasma concentration observed in some of the obstetrical syndromes may be that during these syndromes there is a reduction in the placental production of TFPI (mainly TFPI-2), contributing to the low maternal plasma concentrations detected in patients with PTL, in addition to the thrombin inhibitory effect to TFPI expression on endothelial cells, as above mentioned. Indeed, patients with vascular complications of pregnancy (preeclampsia, eclampsia, placental abruption, fetal growth restriction, and fetal demise) have a lower placental concentration of total TFPI, and TFPI mRNA expression than in women with normal pregnancies.

Other proteins implicated in the inhibitory control of the coagulation cascade are protein S, protein C and protein Z. Protein S is a cofactor to protein C in the inactivation of factors Va and VIIIa. This protein exists in two forms: a free form and a complex form bound
to complement protein C4b-binding protein (C4BP). Only the free form is active\(^80\). Protein S also acts as a TFPI cofactor, in the presence of weak pro-coagulant stimuli, by enhancing the interaction of TFPI with factor Xa while using Ca\(^{2+}\) and phospholipids in the process\(^81\) without increasing inhibition of factor VIIa-TF by TFPI\(^82\). During pregnancy there is a physiologic change in the relationship between the bound and the free forms of protein S in the maternal plasma. The increase in C4BP during gestation reduces free protein S concentration in up to 55% of its value out of pregnant state, reaching its nadir at delivery. Of interest, cesarean delivery and infection exacerbate the reduction in free protein S concentrations\(^81, 83\). Moreover, a functional protein S deficiency can explain a poor response to activated protein C\(^84\).

The association between the alteration of concentration and function of protein S and protein C in the great obstetrical syndromes is not completely clear. The evidence regarding the association of protein S and protein C deficiency and preeclampsia is controversial\(^85, 86\). While some reported an association between protein S deficiency and an increased risk for this syndrome (especially for early onset preeclampsia)\(^85\) others could not demonstrate this effect\(^86\).

There is some evidence regarding the relation of protein S deficiency and increased risk of stillbirth\(^87\) and mid-trimester IUGR\(^88\). An increased risk of stillbirth has been reported in patients with protein S deficiency while the risk was not significantly increased in cases of protein C deficiency\(^87\), and Kupferminc et al\(^88\) found that protein S, but not protein C deficiency, was significantly associated with severe mid-trimester IUGR.

Protein Z, in complex with protein Z-dependent protease inhibitor (ZPI) (Fig. 3)\(^89-91\), acts as a physiologic inhibitor of activation of prothrombin by factor Xa. Protein Z is a vitamin K-dependent plasma glycoprotein\(^92\) that is an essential cofactor for ZPI activity. In the absence of protein Z, the activity of ZPI is reduced by more than 1000-fold\(^91\). Normal pregnancy is characterized by an increased plasma concentration of protein Z\(^93\), probably as a compensation for the increase of factor X concentration. Women with preterm labor without intra-amniotic infection or inflammation and those with vaginal bleeding who delivered preterm had a lower median maternal plasma protein Z concentration than women with a normal pregnancy and those with vaginal bleeding who delivered at term\(^94\). The changes of protein Z concentrations in other pregnancy complications are controversial. Some demonstrated that the median plasma concentration of protein Z in patients with preeclampsia, IUGR, and late fetal death were not significantly different than that of patients with a normal pregnancy\(^95\). Others reported lower median maternal plasma protein Z concentrations in women with preeclampsia or pyelonephritis and higher proportion of protein Z deficiency (defined as protein Z plasma concentration below the 5\(^{th}\) percentile) in patients with preeclampsia or fetal demise than in those with a normal...
pregnancy. Moreover, increased maternal plasma anti-protein Z antibodies concentrations were associated with SGA neonates, fetal demise and preeclampsia. The information presented above suggest that it is not only the concentration of one coagulation factor or anticoagulation protein, but rather the overall balance between the coagulation factors and their inhibitors that increases thrombin generation in the great obstetrical syndromes. Indeed, although preterm labor was not associated with a significant change in the median maternal plasma TF concentration, the TFPI/TF ratio of these patients was lower than that of normal pregnant women, mainly due to decreased TFPI concentrations. This observation was also reported in patients with preterm PROM, and those with preeclampsia. The lower TFPI/TF ratio in patients with preeclampsia occurs despite the increase in the median maternal plasma TFPI concentration observed in these patients. This suggests that the balance between TF and its natural inhibitor may better reflect the overall activity of the TF pathway of coagulation, than the individual concentrations of TF or TFPI. Collectively, these observations suggest that our attention should be focused not only on the coagulation protein but also on their inhibitors since an imbalance between them may contribute to increased thrombin generation leading to the onset of the great obstetrical syndromes.
4.2 Changes in the feto-maternal interface

Normal placental development and the establishment of an adequate feto-maternal circulation are key points for a successful pregnancy. The networks of the placental vascular tree either on the maternal or fetal side are dynamic structures that can be substantially altered in cases of abnormal placentation and trophoblast invasion. The human trophoblast has properties of endothelial cells and can regulate the degree of activation of the coagulation cascade in the intervillous space\textsuperscript{97, 98}. The vilous trophoblasts express heparin sulfate, protein C and protein Z on their surface that serve as anticoagulant that sustain laminar blood flow through the intervillous space. On the other hand, unlike the endothelium of other organs, the trophoblast constantly presents the active placental isoform of TF on its surface\textsuperscript{98-101}. This isoform has a higher affinity for factor VIIa\textsuperscript{102}, which may lead to increased activation of the coagulation cascade. One of the leading pathological processes observed in all these syndromes is thrombosis and vascular abnormality of the placenta at the maternal-fetal interface. The incidence of these pathological processes varies among the different syndromes being more prevalent in preeclampsia, IUGR, and fetal demise than in PTL and preterm PROM\textsuperscript{30, 31, 37, 38}.

4.2.1 Placental pathology in the Great Obstetrical Syndromes

There is a range of placental vascular and thrombotic lesions that are being observed in placentas of patients with pregnancy complications. Thrombotic events of placental vessels can cause an impairment of placental perfusion, leading to FGR, preeclampsia and fetal death as well as in some extents to PTL and preterm PROM\textsuperscript{103, 104}. The frequency of the specific vascular placental lesions varies among these obstetrical syndromes\textsuperscript{105}. Placental vascular lesions are divided into maternal or fetal vascular origin (figure 1-2)\textsuperscript{106, 107}. Lesions of the maternal vascular compartment include placental marginal and retro-placental hemorrhages, lesions related to maternal under perfusion (acute atherosis and mural hypertrophy, increased syncytial knots, villous agglutination, increased intervillous fibrin deposition, villous infarcts)\textsuperscript{106}. Placental fetal vascular obstructive lesions are the result of stasis, hypercoagulability and vascular damage within the fetal circulation of the placenta. Placental fetal vascular abnormalities include: cord-related abnormalities (as torsion of cord, over-coiling, strictures and tight knots\textsuperscript{108}) and vascular lesions consistent with fetal thrombo-occlusive disease (thrombosis of the chorionic plate and stem villous vessels, fibrotic, hypo-vascular and avascular villi\textsuperscript{106}. In addition, villitis of unknown etiology or chronic villitis, defined as lymphohistiocytic
inflammation localized to the stroma of terminal villi but often extending to the small vessels of upstream villi is also associated with obliterative fetal vasculopathy\textsuperscript{106} (Fig. 4-5).

**Preeclampsia:** The classical example for an association between obstetrical syndrome and vascular placental lesions is preeclampsia. Women who develop preeclampsia have an increased rate of abnormalities of the maternal side of the placental circulation and maternal underperfusion\textsuperscript{109, 110}. The frequency of these lesions is inversely related to the gestational age in which the hypertensive disorder was diagnosed. The earliest the development of hypertension/preeclampsia the more severe are the vascular lesions\textsuperscript{111, 112}. Moreover, Kovo et al\textsuperscript{113} reported that the presence of fetal growth restriction in women with preeclampsia increases also the frequency of fetal vascular lesions. Indeed, patients with early-onset preeclampsia complicated by FGR had a higher rate of fetal-vascular supply lesions consistent with fetal thrombo-occlusive disease than women with early-onset disease without FGR\textsuperscript{113}. An assessment of the pathologic changes in placental hemostatic system has been performed in patients with preeclampsia. Teng et al\textsuperscript{114} studied TF and TFPI placental levels in pregnant patients with preeclampsia, compared to normal pregnancies. They found increased TF placental expression and a reduced expression of TFPI-1 and TFPI-2, with a significant correlation between the levels of TF and TFPI-2 between maternal plasma and placenta.

**Fetal growth restriction:** Placentas from pregnancies complicated by FGR are smaller and have significantly increased maternal and fetal vascular lesions compared to placentas from normal pregnancies with appropriate for gestational age neonates (AGA)\textsuperscript{115, 116}. Maternal vascular lesions were detected in about 50% of placentas from pregnancies complicated with FGR at term, compared to only 20% in normal pregnancies, while fetal vascular lesions were observed in 11% of FGR pregnancies compared to only 4% in placentas from normal pregnancies\textsuperscript{113}. Placentas from normotensive pregnancies complicated by early-onset FGR (<34 weeks of gestation) had a higher rate of low placental weight (<10th percentile) and maternal underperfusion, as compared to placentas of women who delivered AGA neonates ≤34 weeks of gestation\textsuperscript{115}. Of interest, placentas from the late onset FGR group (after 34 weeks of gestation), in addition to the high maternal vascular abnormalities, show also more fetal vascular abnormalities, compared with AGA controls who delivered >34 weeks\textsuperscript{117}.

**Fetal demise:** Placental disease has been recognized as an important contributor to unexplained fetal demise. Fetal vascular abnormalities\textsuperscript{105} are extensively involved in early and late fetal death rather than maternal vascular lesions. In fetal death occurring prior to 34 weeks, an earlier and
extended insult in the placental development occurs. On the other hand, late fetal demise is an unpredicted event that is mostly characterized by non-thrombotic cord related lesions and less placental vascular compromise.

**Preterm labor and preterm PROM:** Placental studies in PTL demonstrated a combination of inflammatory and vascular lesions. PTL is generally attributed to an inflammatory response involving the bacterial induction of cytokine and prostanoid production. Finding of histological chorioamnionitis in PTL has established infection and inflammation as a causative factor of preterm birth, moreover, noninfectious trigger may also contribute to the development of preterm labor and in some instances may be evident by placental sterile inflammatory response. In addition, isolated placental vascular lesions, mostly of maternal supply, were reported in 20% of cases of PTL and an additional 20% had combined inflammatory and vascular lesions. Moreover, there are consistent reports describing increased rate of failure of transformation of the spiral arteries in women with preterm labor without intrauterine infection/inflammation and in those with preterm PROM than in women with normal pregnancies. Such findings imply that an inadequate uteroplacental blood flow due to abnormal placentation plays an important role in pathogenesis of preterm parturition.

Collectively, placental vascular lesions were reported in all the great obstetrical syndromes. The severity of these lesions is associated with the timing of diagnosis of the disease. The more severe the vascular injury, the more likely these complications will become clinically evident prior to 34 weeks of gestation. Of interest, vascular lesions often come along with evidence of acute inflammation or lesions associated with chronic inflammatory processes, suggesting that sometimes more than one mechanism is involved in development of a specific obstetrical syndrome.

### 4.3. Hemostatic changes in the amniotic fluid of women with obstetrical syndromes

During normal pregnancy, there is an increase in the amniotic fluid TF concentration. In order to demonstrate the association of hemostatic changes and the development of obstetrical complications, Erez et al. studied the changes in the intra-amniotic concentration of TAT III complexes, as well as TF concentration and activity, in cases of fetal demise and in normal pregnancies.

Patients with a fetal demise had higher median amniotic fluid–TF concentration and activity than those with normal pregnancies. Moreover, among patients with a FD there was a significant correlation (Fig. 6) between the amniotic fluid–TF concentrations and activity.
The median amniotic fluid–TAT III complexes concentration did not differ significantly between the groups (normal pregnancy: median: 66.3 mg/l, range 11.4–2265.4 vs. FD: median: 59.3 mg/l, range: 13.6–15,425.3; P =0.7). In their study, the median amniotic fluid–TF concentration in normal pregnant women was 10 fold higher than in maternal plasma. The changes in amniotic fluid thrombin generation were reported also in women with preterm parturition. Indeed, intra-amniotic infection and/or inflammation is associated with an increased amniotic fluid TAT III complexes (Fig. 7). This is important since it represents an increased thrombin generation in the amniotic cavity during infection and/or inflammation that may contribute to uterine contractility and the development of preterm birth. Of interest, elevated intra-amniotic TAT III concentrations were associated with a shorter amniocentesis to delivery interval and an earlier gestational age at delivery only in patients with preterm labor without intra-amniotic infection or inflammation. This observation suggests that in a subset of patients with preterm labor, activation of the coagulation system can generate preterm parturition and delivery; while in those with intra-amniotic infection and/or inflammation the activation of the coagulation and thrombin generation is a byproduct of the inflammatory process leading to preterm birth.

This represents evidence of the activation and propagation of coagulation cascade, being thrombin generation the witness of the former mechanisms and the inhibitor of the initiation step.

5. Conclusion
The evidence presented herein suggests a role for increased thrombin generation and vascular placental lesions in the pathogenesis of the great obstetrical syndromes. This process can be the result of the contribution of procoagulant and vascular abnormalities as well as inflammatory and infectious mechanisms, representing the starting point for pregnancy complications based on vascular disease. As presented, these changes affect the mother, the placenta, membranes and amniotic fluid. Moreover, preliminary evidence suggest that some of the changes in the hemostatic system in the mother and in the amniotic fluid predate the clinical presentation of the disease. Suggesting that better understanding of the vascular and coagulation changes associated with the great obstetrical syndromes may assist us in earlier detection and the development or introduction of therapeutic modalities for these syndromes.
References


70. KISIEL W, SPRECHER CA, FOSTER DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 1994;84:4384-5.


Figure 1. Thrombin–antithrombin III (TAT) levels in control patients, patients with preterm labor who delivered within 3 weeks, and patients with preterm labor who delivered after 3 weeks. Open diamonds, Mean levels; black error bars, SD. *P <.05, Student-Newman-Keuls method (from Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Am J Obstet Gynecol 2001 Nov;185(5):1059-1063. With permission).

Figure 2. (a) Comparison of median maternal plasma TF concentration between patients with normal pregnancy (n=79), pre-eclampsia (n=133), and women who delivered an SGA neonate (n=61). (b) Comparison of median maternal plasma TFPI concentration between patients with normal pregnancy (n=86), pre-eclampsia (n=133), and women who delivered an SGA neonate.
Figure 3. Factor X activation and protein Z/protein Z-dependent protease inhibitor (ZPI) inhibition of activated factor X. (a) Then formation of the complex of tissue factor (TF) and factor VIIa (FVIIa) at the site of injury and activation of extrinsic coagulation cascade. (b) Activation of circulating factor X by the TFpFVIIa complex in the presence of exposed phospholipids and Ca2+. (c) Inhibition of factor Xa (FXa) by the protein Z/ZPI complex by binding to its active site. Modified from Broze JG, Lancet 2001;357:900–901.
Figure 4. Histologic features of maternal vessel and implantation site reaction patterns: a. Acute atherosclerosis of maternal arterioles in the placental membranes: a cluster of decidual arterioles shows varying stages of fibrinoid necrosis. The vessel at the upper right shows full histologic expression with dark homogenous fibrinoid replacement of the vessel wall accompanied by occasional foamy macrophages ([original magnification is indicated for all panels] X 20). b. Mural hypertrophy of decidual arterioles in the placental membranes: a cluster of arterioles shows medial hypertrophy with the vessel wall occupying greater than one third of total vessel diameter (X 10). c. Muscularized basal plate arteries with accompanying implantation site abnormalities: maternal spiral arteries in the basal plate lack normal trophoblast remodeling and retain their pre-
pregnancy muscular media. Clusters of immature intermediate trophoblast and increased placental giant cells are seen above and below the muscular arteries, respectively (X 10). d. Acute atherosclerosis of muscularized basal plate arteries with accompanying implantation site abnormalities:

three cross sections of a basal plate artery are seen. The two on the left show persistence of the muscular media while the one on the right has undergone fibrinoid necrosis of the media with foamy macrophages (acute atherosclerosis). Clusters of immature intermediate trophoblast are also seen overlying the arteries (X 4). e. Immature intermediate trophoblast: clusters of abnormally small intermediate trophoblast with focal vacuolation are surrounded by an excessive amount of basal plate fibrin. Increased placental site giant cells are also seen at the lower margin (X 10). f. Increased placental site giant cells: numerous multinucleate placental site giant cells, not usually seen in the delivered placenta, are scattered in loose decidual tissue which is devoid of normal intermediate trophoblast and fibrinoid (X 10).
Figure 5. Histologic features of villous and intervillous lesions; a. Increased syncytial knots: aggregates of syncytiotrophoblast nuclei cluster at one or more poles of distal villi in the vicinity of larger stem villi (arrowhead) at the periphery of the lobule ([original magnification is indicated for all panels] X 10). b. Villous agglutination: clusters of degenerating distal villi are adherent to one another and focally enmeshed in fibrin (X 4). c. Distal villous hypoplasia: a long, thin, non-branching stem villus is surrounded by a markedly reduced number of small hypoplastic distal villi (X 10). d. Increased intervillous fibrin: stem villi are surrounded by a mantle of fibrin-type fibrinoid that does not extend to distal villi at the center of the lobule (X 2). e. Nodular intervillous (and intravillous) fibrin: small aggregates of intervillous fibrin adhere to, and are focally reepithelialized by, distal villous trophoblast (X 20). f. Increased intervillous fibrin with intermediate trophoblast (X-cells): stem and distal villi are enmeshed in a matrix of fibrin and fibrinoid containing prominent intermediate trophoblast (arrowhead) (X 10).
Figure 6. Amniotic fluid tissue factor concentration among women with normal pregnancies (median 3710.4 pg/ml, range 2198.8–6268) and patients with a fetal demise (median 8535.4 pg/ml, range 2208.2–125,990.0); (b) Amniotic fluid tissue factor activity among women with normal pregnancies (median 28.4 pM, range 10.2–84.9) and patients with a fetal demise (median 81.6 pM, range 7.2–1603.4). From EREZ O, GOTSCH F, MAZAKI-TOVI S, et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med 2009;22:672-87, with permission.
Table 1

Concentration and activity in maternal plasma of coagulating and anticoagulating factors and their relation with thrombin generation in the great obstetrical syndromes.
Table 1. Concentration and activity in maternal plasma of coagulating and anticoagulating factors and their relation with thrombin generation in the great obstetrical syndromes.

<table>
<thead>
<tr>
<th>Condition</th>
<th>TF concentration and/or activity</th>
<th>TFPI concentration and/or activity</th>
<th>TAT III complexes concentration</th>
<th>Protein Z concentration</th>
<th>Thrombin generation</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premature rupture of membranes</td>
<td>Activity ↑</td>
<td>Concentration ↓</td>
<td>Concentration ↑</td>
<td>Concentration ↓</td>
<td>↑</td>
<td>1-5</td>
</tr>
<tr>
<td></td>
<td>Concentration ↑</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm labor</td>
<td>Activity ↑</td>
<td>Activity =</td>
<td>Concentration ↑</td>
<td>Concentration ↓</td>
<td>↑</td>
<td>1-5</td>
</tr>
<tr>
<td></td>
<td>Concentration =</td>
<td>Concentration ↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fetal demise</td>
<td>Activity =</td>
<td>Concentration =</td>
<td>Concentration ↑</td>
<td>Concentration ↓</td>
<td>↑</td>
<td>1-5</td>
</tr>
<tr>
<td></td>
<td>Concentration =</td>
<td>Concentration ↓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>Activity ↑</td>
<td>Concentration ↓</td>
<td>Concentration ↑</td>
<td>Concentration ↓</td>
<td>↑</td>
<td>1-5</td>
</tr>
<tr>
<td></td>
<td>Concentration ↑</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrauterine growth retardation</td>
<td>Concentration ↓</td>
<td>Concentration =</td>
<td>Concentration ↑</td>
<td>Concentration ↓</td>
<td>↑</td>
<td>1-5</td>
</tr>
</tbody>
</table>


